Printer Friendly

FlowAid Granted Health Canada Medical Device License for FA100 SCCD.

M2 PHARMA-August 23, 2016-FlowAid Granted Health Canada Medical Device License for FA100 SCCD


- US-based medical device maker FlowAid Medical Technologies Corp's FA100 SCCD has received Health Canada MDL License No.: 97539, the company said.

The device treats many circulatory disorders of the lower extremities and prevents many complications.

According to the company, the device introduces a breakthrough in sequential compression therapies and may be a good alternative to the standard pneumatic compression therapies, which create external pressure, and discomfort to the leg.

Patients have enhanced quality of life as they have complete mobility during treatment and can continue their normal daily schedules.

The FlowAid FA100 SCCD is a portable and handheld four-channel device that produces a sequence of muscular contractions through four electrodes placed on the skin of the lower limb.

Three user selectable settings control the frequency of contractions as they pass through muscle tissue for different treatment protocols.

Contractions are distal to proximal (from the feet to the head) and compress the vasculature in a peristaltic wave motion forcing the emptying of the deep veins of the lower limb.

Because of increased circulation in the main and peripheral areas, deoxygenated blood is removed, and oxygen and nutrient rich blood are delivered to the extremities allowing the natural healing process to begin.

FlowAid Medical Technologies was established in 2015 in New York, USA.

((Comments on this story may be sent to

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Aug 23, 2016
Previous Article:Wearable Technology to Revolutionize Biometrics but Privacy Issues Continue, Survey Finds.
Next Article:Gilead Sciences receives European Commission marketing authorisation for Truvada.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters